Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of thrombolytic agents.

H R Lijnen1, D Collen

  • 1Center for Thrombosis and Vascular Research, University of Leuven, Belgium.

Biotechnology Advances
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired fibrinolysis and the risk for coronary heart disease.

Circulation·1996
Same author

Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.

European journal of biochemistry·1996
Same author

Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

Circulation·1996
Same author

A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.

Thrombosis and haemostasis·1996
Same author

Role of tissue factor in embryonic blood vessel development.

Nature·1996
Same author

Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association.

The Journal of biological chemistry·1996
Same journal

Cell surface display for nutritional chemicals: Strategies, mechanisms, and evaluation methods.

Biotechnology advances·2026
Same journal

Advancing synthetic biology with engineered chemically inducible gene regulatory systems.

Biotechnology advances·2026
Same journal

Technology-driven revolution in CO<sub>2</sub> fixation: From natural pathways to programmable Biosystems.

Biotechnology advances·2026
Same journal

Enzymes for CO<sub>2</sub> fixation: Discovery, engineering, and applications.

Biotechnology advances·2026
Same journal

Technological advances in extrachromosomal circular DNA detection.

Biotechnology advances·2026
Same journal

Codon compression and novel codon creation for multiplex non-canonical amino acid incorporation.

Biotechnology advances·2026
See all related articles

Current thrombolytic agents for myocardial infarction have limitations. Research focuses on developing improved plasminogen activators with enhanced potency and specificity for better clot dissolution and fewer side effects.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pharmacology

Background:

  • Existing thrombolytic agents for acute myocardial infarction (AMI) present significant limitations.
  • These limitations include resistance to reperfusion, risk of coronary reocclusion, and bleeding complications.
  • Current therapies often require intravenous administration of large quantities of plasminogen activators.

Purpose of the Study:

  • To address the limitations of current thrombolytic therapies for AMI.
  • To explore novel strategies for developing more effective and safer thrombolytic agents.
  • To identify plasminogen activators with higher potency, specificity, and fibrin-selectivity.

Main Methods:

  • Investigating the development of mutant and variant plasminogen activators.

Related Experiment Videos

  • Exploring chimeric plasminogen activators for improved therapeutic profiles.
  • Examining conjugates of plasminogen activators with monoclonal antibodies.
  • Evaluating plasminogen activators derived from animal or bacterial sources.

    • Main Results:

    • The study outlines various research avenues for enhancing thrombolytic agents.
    • Focus is placed on strategies to overcome resistance, reocclusion, and bleeding.
    • Potential for improved clot-busting therapies is highlighted through diverse approaches.

    Conclusions:

    • There is an ongoing need for superior thrombolytic agents in treating acute myocardial infarction.
    • Multiple innovative strategies are under investigation to improve plasminogen activator efficacy and safety.
    • Future research aims to yield more potent, specific, and fibrin-selective thrombolytic therapies.